- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06793397
En fase 3 -studie for å vurdere CYB003 i stor depressiv lidelse (EMBRACE)
En effektivitet og sikkerhet, fase III, multisenter, dobbeltblind, randomisert kontrollert studie som sammenligner 2 aktive doser av CYB003 og placebo hos kvalifiserte deltakere med stor depressiv lidelse
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Development
- Telefonnummer: 877-361-4003
- E-post: clinicaltrialsinfo@cybin.com
Studiesteder
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Rekruttering
- Royal Prince Alfred Hospital
-
Hovedetterforsker:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australia, 4558
- Rekruttering
- Thompson Brain & Mind Healthcare (TBMH)
-
Hovedetterforsker:
- Adem Can
-
Ta kontakt med:
- Megan Dutton
- Telefonnummer: +61 4160 40977
- E-post: mdutton@tbmh.org.au
-
Ta kontakt med:
- Kristy Smyth
- Telefonnummer: +61 4324 41227
- E-post: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Rekruttering
- Ramsay Clinic
-
Hovedetterforsker:
- Malcolm Hopwood
-
Ta kontakt med:
- Melanie Hurley
- Telefonnummer: 03 9279 3569
- E-post: research.arc@ramsayhealth.com.au
-
Ta kontakt med:
- Grace Monigatti
- Telefonnummer: 03 9279 3569
- E-post: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australia, 3053
- Rekruttering
- Neurocentrix Research
-
Hovedetterforsker:
- David Barton
-
Ta kontakt med:
- Mai-Anh Bui
- Telefonnummer: +61 3 9546 0009
- E-post: mai@neurocentrix.com.au
-
Ta kontakt med:
- Gabriela Gonzalez
- Telefonnummer: +61 3 9959 8375
- E-post: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australia, 3168
- Rekruttering
- Monash University - Notting Hill
-
Ta kontakt med:
- Olivia Lavalette
- Telefonnummer: 0426359494
- E-post: olivia.lavalette@monash.edu
-
Hovedetterforsker:
- Paul Liknaitzky
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35209
- Rekruttering
- UAB Psychiatry and Behavioral Neurology
-
Ta kontakt med:
- Seher Premani
- Telefonnummer: 205-996-1198
- E-post: spremani@uab.edu
-
Hovedetterforsker:
- Peter Hendricks
-
Ta kontakt med:
- Maggie Gossage
- E-post: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Forente stater, 85234
- Rekruttering
- Lighthouse Psychiatry
-
Ta kontakt med:
- Chung Trinh
- Telefonnummer: 435-268-5800
- E-post: ctrinh@neosciclinicalresearch.com
-
Hovedetterforsker:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72204
- Tilbaketrukket
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, Forente stater, 91206
- Rekruttering
- Behavioral Research Specialists, LLC
-
Hovedetterforsker:
- Jesse Carr
-
Ta kontakt med:
- Laisha Uribe
- Telefonnummer: 888-255-5798
- E-post: laisha@brstrials.com
-
Imperial, California, Forente stater, 92251
- Tilbaketrukket
- Sun Valley Research Center
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- CalNeuro Research Group
-
Hovedetterforsker:
- Alexander Bystritsky
-
Ta kontakt med:
- Telefonnummer: 310-208-7144
- E-post: info@calneuroresearch.com
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- Lipov Medical Group
-
Ta kontakt med:
- Brittany Juhlmann
- Telefonnummer: 262-352-8835
- E-post: brittany.juhlmann@stellacenter.com
-
Hovedetterforsker:
- Jacob Moussai
-
Orange, California, Forente stater, 92868
- Rekruttering
- NRC Research Institute
-
Ta kontakt med:
- Christian Ortiz
- Telefonnummer: 714-289-1100
- E-post: cortiz@nrcresearch.com
-
Hovedetterforsker:
- Daniel Chueh
-
Orange, California, Forente stater, 92866
- Rekruttering
- ATP Clinical Research
-
Hovedetterforsker:
- Gustavo Alva
-
Ta kontakt med:
- Sarah Perkins
- Telefonnummer: 949-354-5353
- E-post: sarahp@pnsoc.com
-
San Juan Capistrano, California, Forente stater, 92675
- Rekruttering
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Hovedetterforsker:
- Neelima Kunam
-
Ta kontakt med:
- Telefonnummer: 909-955-5865
- E-post: research@inlandpsych.com
-
Santa Monica, California, Forente stater, 90404
- Rekruttering
- Psychedelic Science Institute
-
Hovedetterforsker:
- Keith Heinzerling
-
Ta kontakt med:
- Telefonnummer: 213-973-7512
- E-post: trialadmin@psychedelicsci.com
-
Stanford, California, Forente stater, 94305
- Tilbaketrukket
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06511
- Rekruttering
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Hovedetterforsker:
- Ben Kelmendi
-
Ta kontakt med:
- Daidre Chamberlain
- Telefonnummer: 203-693-1591
- E-post: enact@yale.edu
-
Ta kontakt med:
- Terrence Ching
- Telefonnummer: 502-612-1127
- E-post: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32256
- Rekruttering
- CNS Healthcare
-
Ta kontakt med:
- Telefonnummer: 904-281-5757
-
Hovedetterforsker:
- John Mark Joyce
-
Maitland, Florida, Forente stater, 32751
- Rekruttering
- Accel Research Sites - Maitland
-
Ta kontakt med:
- Telefonnummer: 407-644-1165
-
Hovedetterforsker:
- Andrea Marrafino
-
Naples, Florida, Forente stater, 34105
- Rekruttering
- Aqualane Clinical Research
-
Hovedetterforsker:
- Matthew Baker
-
Ta kontakt med:
- Rachel Novella
- Telefonnummer: 239-529-6780
- E-post: Rachel@Aqualaneresearch.com
-
Tampa, Florida, Forente stater, 33634
- Rekruttering
- K2 Medical Research Tampa
-
Hovedetterforsker:
- Kelley Wilson
-
Ta kontakt med:
- Jessica Myers
- Telefonnummer: 352-500-5252
- E-post: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Tilbaketrukket
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, Forente stater, 30060
- Rekruttering
- Psych Atlanta
-
Hovedetterforsker:
- Michael Banov
-
Ta kontakt med:
- Telefonnummer: 770-422-2846
- E-post: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rekruttering
- Rush University
-
Hovedetterforsker:
- Joshua Eloge
-
Ta kontakt med:
- Stephanie Gutierrez
- Telefonnummer: 312-942-8995
- E-post: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, Forente stater, 70006
- Tilbaketrukket
- Tandem Clinical Research
-
New Orleans, Louisiana, Forente stater, 70115
- Rekruttering
- Atlas Psychiatry
-
Ta kontakt med:
- Milton Boresoff
- Telefonnummer: 504-899-1682
- E-post: m.boresoff@atlaspsychiatry.com
-
Hovedetterforsker:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21224
- Tilbaketrukket
- Johns Hopkins Medicine
-
Rockville, Maryland, Forente stater, 20850
- Har ikke rekruttert ennå
- Sunstone Medical, PC
-
Ta kontakt med:
- Manish Agrawal, MD
- Telefonnummer: 301-750-3401
- E-post: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02116
- Rekruttering
- Adams Clinical Boston
-
Hovedetterforsker:
- Darin Dougherty
-
Ta kontakt med:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-post: info@adamsclinical.com
-
Watertown, Massachusetts, Forente stater, 02472
- Rekruttering
- Adams Clinical Watertown
-
Hovedetterforsker:
- Stephanie Ellickson
-
Ta kontakt med:
- Participant Navigators
- Telefonnummer: 617-404-4714
- E-post: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, Forente stater, 55347
- Rekruttering
- Institute for Integrative Therapies
-
Hovedetterforsker:
- Manoj Doss
-
Ta kontakt med:
- Sena Ostwalt
- Telefonnummer: 6512808774
- E-post: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, Forente stater, 55427
- Har ikke rekruttert ennå
- The Remedy Mental Health
-
Ta kontakt med:
- Emmanuel Arhin
- Telefonnummer: (651) 382-9518
- E-post: emmanuel.arhin@theremedymn.com
-
Hovedetterforsker:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89119
- Rekruttering
- Redbird Research, LLC
-
Hovedetterforsker:
- Jelena Kunovac
-
Ta kontakt med:
- Telefonnummer: 702-577-2000
- E-post: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, Forente stater, 08755
- Rekruttering
- Bio Behavioral Health
-
Ta kontakt med:
- Jessica Sutton
- Telefonnummer: 732-244-2299
- E-post: jessica@bbhnj.com
-
Hovedetterforsker:
- Ashok Patel
-
-
New York
-
New York, New York, Forente stater, 10032
- Har ikke rekruttert ennå
- New York State Psychiatric Institute
-
Hovedetterforsker:
- Natalie Gukasyan
-
Ta kontakt med:
- Alexandra Mackay
- Telefonnummer: 212-342-1424
- E-post: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, Forente stater, 10029
- Rekruttering
- Adams Clinical Harlem
-
Ta kontakt med:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-post: info@adamsclinical.com
-
Hovedetterforsker:
- Wesley Gregory
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Adams Clinical Bronx
-
Hovedetterforsker:
- Shama Farooq
-
Ta kontakt med:
- Participant Navigators
- Telefonnummer: 917-454-3746
- E-post: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73112
- Tilbaketrukket
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Adams Clinical Philadelphia
-
Hovedetterforsker:
- Cassie Blanchard
-
Ta kontakt med:
- Participant Navigators
- Telefonnummer: 267-376-0266
- E-post: info@adamsclinical.com
-
Philadelphia, Pennsylvania, Forente stater, 19462
- Rekruttering
- Flourish Research Philadelphia
-
Hovedetterforsker:
- Rachna Saralkar
-
Ta kontakt med:
- Telefonnummer: 215-614-5606
-
-
Texas
-
Austin, Texas, Forente stater, 78737
- Tilbaketrukket
- Austin Clinical Trial Partners
-
DeSoto, Texas, Forente stater, 75115
- Rekruttering
- Adams Clinical Dallas
-
Hovedetterforsker:
- Rajinder Shiwach
-
Ta kontakt med:
- Participant Navigators
- Telefonnummer: 469-379-2494
- E-post: info@adamsclinical.com
-
Fort Worth, Texas, Forente stater, 76104
- Tilbaketrukket
- North Texas Clinical Trials
-
Houston, Texas, Forente stater, 77046
- Rekruttering
- Brain Health Consultants and TMS Center
-
Hovedetterforsker:
- Lauren Marangell
-
Ta kontakt med:
- Telefonnummer: 713-489-5000
- E-post: info@brainhealthconsultants.com
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Flourish Research San Antonio
-
Hovedetterforsker:
- Parke Hedges
-
Ta kontakt med:
- Xavier Martinez
- Telefonnummer: 237 210-949-0122
- E-post: xmartinez@flourishresearch.com
-
Ta kontakt med:
- Andrea Gomez
- Telefonnummer: 122 210-949-0122
- E-post: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, Forente stater, 98201
- Har ikke rekruttert ennå
- Core Clinical Research
-
Ta kontakt med:
- Maria Golescu
- Telefonnummer: 425-443-9551
- E-post: maria.golescu@ccrtrial.com
-
Hovedetterforsker:
- James Knutson
-
Seattle, Washington, Forente stater, 98104
- Rekruttering
- Seattle Neuropsychiatric Treatment Center
-
Hovedetterforsker:
- Rebecca Allen
-
Ta kontakt med:
- Telefonnummer: 5 206-467-6300
- E-post: research@seattlentc.com
-
-
-
-
-
Athens, Hellas, 12462
- Rekruttering
- Attikon University Hospital
-
Hovedetterforsker:
- Nikolaos Smyrnis
-
Ta kontakt med:
- Thomas Karantinos
- Telefonnummer: +30697466610
- E-post: tkarantinos@gmail.com
-
Athens, Hellas, 11528
- Rekruttering
- Eginitio Hospital
-
Hovedetterforsker:
- Nikos Stefanis
-
Ta kontakt med:
- Adam Adamopoulos
- Telefonnummer: +30 6976032181
- E-post: adam_adamopoulos@yahoo.com
-
Thessaloniki, Hellas, 56404
- Rekruttering
- Papageorgiou General Hospital
-
Hovedetterforsker:
- Georgios Papazisis
-
Ta kontakt med:
- Ogla Vampertzi
- Telefonnummer: +306973852659
- E-post: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Irland, D24 WK80
- Rekruttering
- Sheaf House - Tallaght Adult Mental Health Service
-
Hovedetterforsker:
- John Kelly
-
Ta kontakt med:
- Ann Connolly
- Telefonnummer: +353 8616 79619
- E-post: aconnolly@crp.healthcare
-
Galway, Irland, H91 VE03
- Rekruttering
- La Nua Day Hospital Mental Health Centre
-
Ta kontakt med:
- Prathyusha Nedunuru
- Telefonnummer: +353 874283750
- E-post: pnedunuru@crp.healthcare
-
Hovedetterforsker:
- Shane McInerney
-
-
-
-
-
Bialystok, Polen, 15-272
- Tilbaketrukket
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Polen, 85-133
- Rekruttering
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Ta kontakt med:
- Franciszek Lauchut
- Telefonnummer: +48 790 219 501
- E-post: f.lachut@pro-mente.pl
-
Hovedetterforsker:
- Katarzyna Lachut
-
Gdansk, Polen, 80-546
- Rekruttering
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Ta kontakt med:
- Monika Drzewiecka
- Telefonnummer: +48 508-348-938
- E-post: m.drzewiecka@pihouse.pl
-
Hovedetterforsker:
- Hanna Badzio-Jagiello
-
Gdansk, Polen, 80-214
- Har ikke rekruttert ennå
- UCK
-
Hovedetterforsker:
- Wieslaw Jerzy Cubala
-
Ta kontakt med:
- Natalia Sudol
- Telefonnummer: +48 669 439 740
- E-post: nat.sudol13@gmail.com
-
Warsaw, Polen, 02-957
- Har ikke rekruttert ennå
- Department of Pharmacology and Physiology of CNS
-
Hovedetterforsker:
- Justyna Holka-Pokorska
-
Warsaw, Polen, 02-172
- Rekruttering
- MTZ Clinical Research Powered by Pratia
-
Hovedetterforsker:
- Monika Gawlowicz
-
-
-
-
-
Cambridge, Storbritannia, CB1 2EU
- Rekruttering
- Cambridge University Hospital NHS
-
Hovedetterforsker:
- Liliana Galindo
-
Ta kontakt med:
- Tracy Assari
- Telefonnummer: +44 1223 219751
- E-post: t.assari@nhs.net
-
Ta kontakt med:
- Emma Tudor
- Telefonnummer: +44 1223 219751
- E-post: Emma.tudor@cpft.nhs
-
Doncaster, Storbritannia, DN4 8QN
- Rekruttering
- Clerkenwell Health - Doncaster
-
Hovedetterforsker:
- Paul Morrison
-
Ta kontakt med:
- Celia Creaghan
- Telefonnummer: +44 7849 640886
- E-post: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Storbritannia, EH16 4TJ
- Har ikke rekruttert ennå
- NHS Research Scotland
-
Hovedetterforsker:
- Donald MacIntyre
-
Ta kontakt med:
- Carrie Wardhaugh
- Telefonnummer: +44 1315375867
- E-post: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Storbritannia, G51 4TF
- Har ikke rekruttert ennå
- Queen Elizabeth University Hospital
-
Hovedetterforsker:
- Maytal Wolfe
-
Ta kontakt med:
- Rebecca Baird
- E-post: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Storbritannia, L7 8XP
- Har ikke rekruttert ennå
- Royal Liverpool Hospital
-
Ta kontakt med:
- Rachel Crick
- Telefonnummer: +44730 861 3597
- E-post: Rachel.Crick@merseycare.nhs.uk
-
Hovedetterforsker:
- Fabian Devlin
-
London, Storbritannia, EC2Y 8EA
- Rekruttering
- St Pancras Clinical Research
-
Hovedetterforsker:
- Martin Johnson
-
Ta kontakt med:
- Participant Engagement Team
- Telefonnummer: +44 20 38651142
- E-post: studyinformation@stpancrasclinical.com
-
London, Storbritannia, W1U 6RP
- Rekruttering
- Clerkenwell Health - Baker Street
-
Hovedetterforsker:
- Alishah Suleman
-
Ta kontakt med:
- Takunda Gwenhure
- Telefonnummer: +44 2038974867
- E-post: tgwenhure@clerkenwellhealth.com
-
Ta kontakt med:
- Victor Jardim
- Telefonnummer: +44 2038974867
- E-post: vjardim@clerkenwellhealth.com
-
London, Storbritannia, W1G9 RU
- Rekruttering
- Re:Cognition Health
-
Hovedetterforsker:
- Dimitrios Paschos
-
Ta kontakt med:
- Telefonnummer: +44-0800-802-1030
-
London, Storbritannia, SE5 9RS
- Rekruttering
- King's College London
-
Ta kontakt med:
- Catheine Bird
- E-post: catherine.bird@kcl.ac.uk
-
Ta kontakt med:
- Paige Seath
- E-post: paige.seath@kcl.ac.uk
-
Hovedetterforsker:
- James Rucker
-
London, Storbritannia, W1G 8DR
- Tilbaketrukket
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Storbritannia, NE4 5PL
- Rekruttering
- Edwardson Building - Campus for Ageing and Vitality
-
Ta kontakt med:
- Victoria Wilson
- Telefonnummer: +44 191 246 8647
- E-post: victoria.wilson3@cntw.nhs.uk
-
Ta kontakt med:
- Rebecca Woodhouse
- E-post: Rebecca.Woodhouse@cntw.nhs.uk
-
Hovedetterforsker:
- Mourad Wahba
-
Reading, Storbritannia, RG7 8PA
- Rekruttering
- Ascend Clinical Research
-
Hovedetterforsker:
- Pamela Walters
-
Ta kontakt med:
- Alexandra Diaz
- Telefonnummer: +44 118 3045905
- E-post: adiaz@ascendclinical-research.com
-
Sheffield, Storbritannia, S4 7QQ
- Rekruttering
- Sheffield Health and Social Care NHS Foundation Trust
-
Hovedetterforsker:
- William Gann
-
Ta kontakt med:
- Mishell Cunningham
- Telefonnummer: +44 114 271 6731
- E-post: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
-
Prague, Tsjekkia
- Har ikke rekruttert ennå
- Institute of neuropsychiatric Care (INEP)
-
Hovedetterforsker:
- Alexander Nawka
-
Ta kontakt med:
- Telefonnummer: +420 222 201 020
- E-post: info@inep.cz
-
Prague, Tsjekkia
- Har ikke rekruttert ennå
- Psyon s.r.o.
-
Hovedetterforsker:
- Tomas Palenicek
-
Ta kontakt med:
- Telefonnummer: +420 774 401 161
- E-post: info@psyon.cz
-
Předměstí, Tsjekkia
- Har ikke rekruttert ennå
- A-SHINE s.r.o.
-
Hovedetterforsker:
- Lubos Janu
-
Ta kontakt med:
- Blanka Vopelková
- Telefonnummer: +490 777 732 244
- E-post: blanka.vopelkova@seznam.cz
-
-
-
-
-
Berlin, Tyskland, 10117
- Har ikke rekruttert ennå
- Charité Universitaetsmedizin Berlin
-
Hovedetterforsker:
- Michael Koslowski
-
Ta kontakt med:
- Telefonnummer: +49 30 450 617734
- E-post: psychedelika-studien@charite.de
-
Frankfurt am Main, Tyskland, 60528
- Har ikke rekruttert ennå
- University Hospital Frankfurt
-
Hovedetterforsker:
- Andreas Reif
-
Ta kontakt med:
- Tanja Scharf
- Telefonnummer: +49 69 6301 86078
- E-post: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Tyskland, 68159
- Har ikke rekruttert ennå
- Central Institute of Mental Health
-
Ta kontakt med:
- Karin Bopp
- Telefonnummer: 3016 +49 621 1703 3163
- E-post: Karin.bopp@zi-mannheim.de
-
Hovedetterforsker:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Tyskland, 66421
- Har ikke rekruttert ennå
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Hovedetterforsker:
- Matthias Riemenschneider
-
Ta kontakt med:
- Christine Geiger
- Telefonnummer: +49 6841 1624227
- E-post: christine.geiger@uks.eu
-
Ta kontakt med:
- Aline Freer
- Telefonnummer: +49 6841 1614219
- E-post: aline.freer@uks.eu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Eksperimentell: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Placebo komparator: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Tidsramme: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Tidsramme: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Tidsramme: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Tidsramme: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Felix Mazer, Cybin IRL Limited
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CYB003-003
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .